Incidence and determinants of achieving HBsAg <100 IU/mL in HBeAg-negative CHB patients with nucleos(t)ide analogue treatment

Incidence and determinants of achieving HBsAg <100 IU/mL in HBeAg-negative CHB patients with nucleos(t)ide analogue treatment

Quantitative hepatitis B serum antigen (HBsAg) level <100 IU/mL has been proposed as one of the key criteria for partial cure for chronic hepatitis B (CHB) and as an important threshold for stopping nucleos(t)ide analogues (NAs) with a finite therapeutic strategy. We investigated the incidence an...

Full description

Saved in:
Bibliographic Details
Main Authors: Jian Wang, Tao Fan, Zhiyi Zhang, Li Zhu, Shaoqiu Zhang, Ye Xiong, Chun Shan, Chao Jiang, Shengxia Yin, Xin Tong, Renling Yao, Juan Xia, Xiaomin Yan, Yu Shi, Yuxin Chen, Xingxiang Liu, Huali Wang, Haixia Zhang, Chuanwu Zhu, Qun Zhang, Chao Wu, Rui Huang
Format: Article
Language:English
Published: Taylor & Francis Group 2025-08-01
Series:Emerging Microbes and Infections
Subjects:
chronic hepatitis B
nucleos(t)ide analogues
hepatitis B surface antigen
antiviral therapy
Online Access:https://www.tandfonline.com/doi/10.1080/22221751.2025.2552718
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/22221751.2025.2552718

Similar Items